I. Overview

In recent years, the incidence of pancreatic cancer has been increasing significantly both at home and abroad. 2021 statistics show that among all malignant tumors in the United States, pancreatic cancer ranks 10th in new cases in men and 9th in women.
In the United States, pancreatic cancer ranks 10th in men and 9th in women among all malignancies, and accounts for the 4th highest malignancy-related mortality.
The fourth highest rate of malignancy-related mortality. The National Cancer Center of China 2021 statistics show that pancreatic cancer is the 10th most common malignancy among men and the 9th most common among women in China.
The incidence of pancreatic cancer is the 7th most common malignant tumor among men, the 11th most common among women, and the 6th most common malignant tumor-related mortality in China.
(The pancreatic cancer mentioned in this paper refers specifically to pancreatic cancer. (All pancreatic cancers mentioned in this article refer specifically to pancreatic conduit adenocarcinoma.
(The pancreatic cancer mentioned in this article refers to pancreatic ductal adenocarcinoma)
In recent years, with the development of imaging, endoscopy, pathology and other disciplines, the diagnosis of pancreatic cancer has been improved.
In recent years, with the development of imaging, endoscopy and pathology, the diagnosis of pancreatic cancer has been improved.
In recent years, with the development of imaging, endoscopy, pathology and other disciplines, the diagnosis of pancreatic cancer has improved.
and nitrozumab, etc.) have brought opportunities and advances in the treatment of pancreatic cancer.
In order to further standardize the practice of pancreatic cancer diagnosis and treatment in China, it is important to provide the best treatment for the patients.
In order to further standardize pancreatic cancer diagnosis and treatment in China, improve the level of pancreatic cancer diagnosis and treatment in medical institutions, and improve pancreatic cancer treatment.
To further standardize the practice of pancreatic cancer treatment in China, improve the level of pancreatic cancer treatment in medical institutions, improve the prognosis of pancreatic cancer patients, and ensure medical quality and medical safety, this guideline is formulated.
In order to further standardize pancreatic cancer treatment in China, improve the level of pancreatic cancer treatment in medical institutions, improve the prognosis of pancreatic cancer patients, and ensure medical quality and medical safety, this guideline is formulated. Although this guideline is intended to assist in clinical decision-making, it does not incorporate all possible clinical changes.
This guideline is only applicable to pancreatic ductal carcinoma. This guideline applies only to malignancies of pancreatic ductal epithelial origin.
This guideline applies only to malignant tumors of pancreatic ductal epithelial origin.